FOR IMMEDIATE RELEASE
Wednesday 14th January, 2026 – Hale Animal Health, a New Zealand-based veterinary pharmaceutical company, today announced the successful completion of its latest capital raise, securing NZD $4 million from existing shareholders and welcoming Arrow Ventures as a new strategic investor.
This funding marks a significant milestone for Hale Animal Health as the company advances its mission to improve the quality of life for companion animals through science and innovation. The capital will be used to propel Hale into the next phase of development and trials following the completion of a large-scale clinical trial involving 112 dogs across New Zealand.
The recently completed trial focused on Hale’s lead product, a cannabinoid-based medicine designed to treat dogs suffering from osteoarthritis (OA), a condition that affects a significant proportion of the canine population. OA can cause chronic pain and reduced mobility, and while traditional medicines exist, many dogs cannot tolerate them due to side effects or lack of efficacy. Hale’s product aims to provide an alternative that delivers pain relief comparable to existing treatments but with a superior safety profile, addressing a critical unmet need in veterinary medicine.
“This capital raise is a pivotal moment for Hale” said Leila de Koster, CEO of Hale Animal Health. “With the support of our existing shareholders and the addition of Arrow Ventures, we are well positioned to build on the success of our latest clinical trial and move forward with the next stage of development. Our goal is to deliver evidence-based therapies that address underserved needs in veterinary medicine, and this investment brings us closer to achieving that vision.”
Troy Merry, Chief Operations Officer of Arrow Ventures, added: “We are excited to partner with Hale Animal Health as they lead the way in developing innovative, clinically validated solutions for companion animals. Their commitment to rigorous research and regulatory excellence aligns perfectly with our investment philosophy, and we look forward to supporting their growth and impact in the veterinary pharmaceutical space.”
With these milestones achieved, Hale Animal Health is now focused on advancing its pipeline of therapies, including one of the world’s first clinically trialled and registered cannabinoid-based medicines for pets.
–ENDS–
For media enquiries, please contact:
Leila de Koster
CEO
Hale Animal Health
leila@haleanimal.co.nz
02041223412
www.haleanimal.co.nz
About Hale
Hale Animal Health is a New Zealand-based veterinary pharmaceutical company committed to improving the quality of life for companion animals through innovation and science. Headquartered in Auckland New Zealand, Hale is developing one of the world’s first clinically trialled and registered cannabinoid-based medicines for pets. With a focus on rigorous research, regulatory excellence, and animal wellbeing, Hale is building a pipeline of evidence-based therapies to address some of the most pressing needs in veterinary medicine.